Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Congress of the Brazilian Association of Pharmaceutical Sciences/ABCF. Unidade: FCF
Subjects: COLITE, ANTI-INFLAMATÓRIOS
ABNT
SILVA, Marina de Paula et al. Beneficial effects of infliximab therapy are abrogated by the absence of endogenous annexin A1 in murine experimental colitis. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Disponível em: http://www.ivabcfcongress.com.br/arquivos/trabalhos-cientificos.pdf. Acesso em: 04 set. 2024. , 2018APA
Silva, M. de P., Rocha, G. H. O. da, Oliani, S. M., & Farsky, S. H. P. (2018). Beneficial effects of infliximab therapy are abrogated by the absence of endogenous annexin A1 in murine experimental colitis. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. Recuperado de http://www.ivabcfcongress.com.br/arquivos/trabalhos-cientificos.pdfNLM
Silva M de P, Rocha GHO da, Oliani SM, Farsky SHP. Beneficial effects of infliximab therapy are abrogated by the absence of endogenous annexin A1 in murine experimental colitis [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2018 ; 54 30 res. 173.[citado 2024 set. 04 ] Available from: http://www.ivabcfcongress.com.br/arquivos/trabalhos-cientificos.pdfVancouver
Silva M de P, Rocha GHO da, Oliani SM, Farsky SHP. Beneficial effects of infliximab therapy are abrogated by the absence of endogenous annexin A1 in murine experimental colitis [Internet]. Brazilian Journal of Pharmaceutical Sciences. 2018 ; 54 30 res. 173.[citado 2024 set. 04 ] Available from: http://www.ivabcfcongress.com.br/arquivos/trabalhos-cientificos.pdf